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Abstract: The recent development of induced pluripotent stem (iPS) cell technology brings cell and gene therapies to pa-
tients one large step closer to reality. Technical improvements in various research fields sometimes come together fortui-
tously, leading to approaches to treating disease. If iPS cell technology continues to progress smoothly as expected and is 
actually applied to patients, the next logical step to ensuring the success of iPS cell therapy is to make use of next-next 
generation DNA sequencing technology and bioinformatics of recipient genomes. Before a patient-derived iPS cell colony 
is used for clinical therapy in a patient, the colony should undergo whole-genome DNA sequencing, thus avoiding risks 
associated with spontaneously mutagenized iPS cells. Researchers participating in the Human Genome Project need to 
take full advantage of both technologies—iPS cell technology and DNA sequencing—as doing so will help us achieve the 
original long-term goal of the project: developing therapies that will benefit human health. 
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  Induced pluripotent stem (iPS) cells can be produced by 
introducing four transcriptional factors—Oct4, Sox2, Klf4, 
and c-Myc—into embryonic or adult somatic cells by means 
of a retroviral vector [1]. The retroviral vector system allows 
the efficient and simultaneous transfection of the four tran-
scription factors into primary cultured cells, enabling them to 
continuously express foreign genes for more than two weeks. 
Because iPS technology possesses great potential for a wide 
range of applications, including the development of therapies 
for diseases, several researchers worldwide have tested its 
reproducibility and have improved the technology exten-
sively [2]. During this refinement, researchers had to over-
come several challenges, such as how to reprogram human 
somatic cells to become pluripotent cells [3, 4]; and how to 
produce iPS cells through non-integrating gene-delivery sys-
tems [5, 6]. Initially, retrovirus vectors were integrated into 
mouse and human genomes randomly, which is necessary 
for the continuous expression of the four reprogramming 
factors. Random integration of the vector, however, may 
activate or disrupt genes located near the integration site, 
leading to tumorigenicity. To solve this problem, researchers 
have recently developed an adenoviral vector [5] and re-
peated transfection protocol of expression plasmids [6]. De-
spite these efforts, the possibility that a piece of the vector 
will integrate into the recipient cells cannot be excluded.  
  Currently, the hottest competition in research and the 
drug-discovery field involves the identification of small 
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molecules that can replace potentially harmful factors in-
volved in the induction process [7-11], such as c-Myc, a 
well-known oncogene, and Klf4, a potential oncogene. The 
identification of additional small molecules is now on the 
horizon, as the individual roles Oct4, Sox2, Klf4, and c-Myc 
play in converting somatic cells into pluripotent cells have 
recently been clarified [12]. Nonetheless, it remains un-
known whether such small molecules will be safer in the 
long-term than the four reprogramming factors.  
  Another problem daunting current iPS cell methodolo-
gies is that the long-term incubation of primary cultured cells 
needed to generate iPS cells may also cause unexpected mu-
tations to accumulate in the iPS cell genome. In fact, recent 
analyses of human embryonic stem (hES) cells cultured over 
long periods have reported recurrent genomic instability in 
the human genome [13, 14]. Thus, before patient-derived iPS 
cells are clinically applied to the patient, the iPS cells need to 
be screened for unexpected mutations. This can be achieved 
by subjecting the cells to whole-genome DNA sequencing.  
  Since the completion of the Human Genome Project, 
genome researchers have shifted their interest to personal 
genomics. Next and next-next generation DNA sequencing 
permits the re-sequencing of entire human genomes in a 
short time and at low costs [15, 16]. Pacific Biosciences will 
soon make commercially available a large-scale DNA se-
quencer capable of performing real-time DNA sequencing 
from single polymerase molecules [17]. Many researchers in 
both academia and biotechnology are pursuing the “$1,000 
genome” using single-molecule approaches [18]. Another 
company, Complete Genomics, recently announced its plans 304    Current Genomics, 2009, Vol. 10, No. 5  Manabu Nakayama 
to start offering a human genome sequencing service for 
companies and academic institutions in 2009, charging 
$5,000 per genome. State-of-the-art breakthroughs such as 
next-next generation DNA sequencing will enable us to rap-
idly assess the entire genome of autologous, patient-derived 
iPS cells before they are used in patients. This will reduce 
the risk of introducing artificial mutations into the patient.  
  The low efficiency of current iPS cell methods can be 
avoided by using human keratinocytes derived from patients’ 
hair follicles and reprogramming them into iPS cells, a proc-
ess which has shown to be rapid and highly efficient [19]. 
Using keratinocytes is very advantageous in that patients 
experience fewer burdens, as keratinocytes are isolated by 
plucking a patient’s hair. In the future, even patients with 
genetic disorders will receive cell and gene therapies, al-
though they might benefit from iPS technology first. Indeed, 
treating these patients with gene therapy is imminent, as the 
principle underlying the treatment of genetic disorders has 
already been demonstrated through the use of homologous 
recombination and gene-targeting techniques to repair a gene 
with a disease-specific mutation in human iPS cells [20]. As 
iPS technology continues to progress rapidly, we can expect 
that, in the near future, iPS cells derived from keratinocytes 
will be generated by using only small molecules, replacing 
the four transcription factors, or by using a non-integrating 
gene-delivery method of introducing a minimal number of 
reprogramming factors.  
  Generally, several iPS colonies are produced during the 
initial stages of reprogramming. Clinicians, however, usually 
select only one iPS colony before differentiating the cells to 
the needed cell type (e.g., hemocyte, pancreatic -cell, car-
diac muscle cell, or neuron) and introducing the cells into 
patients. By determining the entire DNA sequence of some 
iPS colonies and comparing the sequence with the DNA se-
quence of the patient’s genome, clinicians can confirm iPS 
cell quality and select cells that lack mutations and/or those 
not susceptible to unexpected genomic changes. Cells con-
taining spontaneous mutations, unexpected genomic 
changes, or pieces of vector integrated into the genome can 
be identified and discarded, thus averting potential risks of 
tumorigenicity and unpredictable results. Before the advent 
of rapid, large-scale DNA sequencing technologies, the crite-
ria used by researchers and clinicians to select an iPS cell 
colony for future transplantation was whether the cells ap-
peared healthy. Unlike this intuitional selection method, 
whole-genome DNA sequencing of iPS cells for clinical use 
provides a solid way to select iPS cells intended for trans-
plantation, safeguarding recipient patients from the potential 
risk of tumor formation.  
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